> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eiger Bio NDA for Rare Preemature Aging Disease
- URL: https://www.fdaweb.com/eiger-bio-nda-for-rare-preemature-aging-disease/
- Published: 2020-11-25T12:00:00.000Z
- Updated: 2026-09-14T16:38:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148172

FDA has approved an Eiger BioPharmaceuticals NDA for Zokinvy (lonafarnib) for treating Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies. The ultra-rare, genetic, premature aging diseases accelerate mortality in young patients, according to the company. Untreated children with Progeria die of heart disease at an average age of 14.5 years, it says, adding that there are 20 children and young adults with the disease in the U.S.

Approval is based on data showing that Zokinvy reduced the incidence of mortality by 60%, and increased average survival time by 2.5 years, Eiger says. The most commonly reported adverse reactions were gastrointestinal (vomiting, diarrhea, nausea), and most were mild or moderate, it says.